Lifecore Biomedical
LFCR
95 hedge funds and large institutions have $334M invested in Lifecore Biomedical in 2017 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
1.09% more ownership
Funds ownership: 92.71% → 93.8% (+1.1%)
1% more funds holding
Funds holding: 94 → 95 (+1)
9% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 32
11% less capital invested
Capital invested by funds: $376M → $334M (-$41.8M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Walthausen & Co
Malta,
New York
|
+$8.41M |
| 2 |
Bank of New York Mellon
New York
|
+$1.47M |
| 3 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
+$699K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$429K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$407K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
-$1.85M |
| 2 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
-$1.49M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.02M |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$836K |
| 5 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
-$786K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAM
101
Panagora Asset Management
Boston,
Massachusetts
| – | -$144K | -9,714 | Closed |
|
|
PCM
102
Prelude Capital Management
New York
| – | -$34K | -2,300 | Closed |
|
103
US Bancorp
Minneapolis,
Minnesota
| – | -$2K | -109 | Closed |
|
104
AssetMark Inc
Concord,
California
| – | -$448 | -34 | -85% |
|
LFCR Hedge Fund Activity: Q3 2017 in Review
95 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q3 2017, worth a combined $334M — down 11% from $376M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LFCR positions and 9 closed out — a net gain of 1 holder — while 29 added to existing stakes and 32 trimmed.
The largest buyer was Walthausen & Co, adding an estimated $8.41M. The largest seller was Ariel Investments, cutting an estimated $1.85M.
- 95 institutional investors held Lifecore Biomedical (LFCR) as of Q3 2017, up from 94 in Q2 2017.
- Funds reported $334M of Lifecore Biomedical stock for Q3 2017, down 11% quarter-over-quarter.
- 10 funds opened new Lifecore Biomedical positions in Q3 2017 and 9 closed out, a net change of +1 holder.
- The largest Lifecore Biomedical buyer in Q3 2017 was Walthausen & Co, an estimated $8.41M added.
- The largest Lifecore Biomedical seller in Q3 2017 was Ariel Investments, an estimated $1.85M sold.
Based on aggregated 13F filings for Q3 2017.